Company

Saol Therapeutics Inc.

Saol Therapeutics Inc., based in Roswell, Georgia, develops treatments for CNS disorders and orphan diseases.

About

Founded in 2015 and headquartered in Roswell, Georgia, US, Saol Therapeutics Inc. develops treatments for central nervous system disorders and orphan diseases, including pain management and spasticity. Its lead product, SL1009, uses sodium dichloroacetate to treat Pyruvate Dehydrogenase Complex Deficiency and is paired with a genetic test for pediatric patients. In September 2026, Oaktree Capital Management invested USD 115 million in the company. Thomas Whelan is the founder and David Penake is CEO.

2Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in